PubMed HealthSearch

PubMed · 3051685

[Oncogene expression in colonic cancers].

Abstract

The expression of oncogenes plays a central role in the regulation of cell growth in normal and neoplastic tissue. Techniques developed recently (blot and in situ hybridization), enable the quantitative detection and topographical localization of oncogene expression at DNA and RNA level. In colonic adenomas and carcinomas and in non neoplastic mucosa of the large bowel, expression products of the oncogenes Ha-ras, Ki-ras, fos, and c-myc were detected. In most tumors a significant overexpression--as compared to the normal mucosa--of Ha-ras, Ki-ras, and fos mRNA was found. The overexpression of oncogenes, however, did not correlate with tumor progression, neither qualitatively nor quantitatively. According to recent studies (4, 7) it can be concluded, that the expression of the Ki-ras gene altered by a single point mutation, contributes significantly to the initiation and progression of epithelial neoplasias of the colon mucosa. It can be concluded, therefore, that the demonstration of oncogene expression products will play an important role in tumor diagnosis in the future.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Höfler. 1988-06-30. [Oncogene expression in colonic cancers].. https://pubmed.ncbi.nlm.nih.gov/3051685/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Patients' perception of symptoms in colorectal cancer. A cause of delay in diagnosis and treatment].

A questionnaire was given to a series of 50 patients referred for colorectal cancer to the Department of Surgical Gastroenterology at Hvidovre Hospital, Copenhangen. The patients were asked about the length of the period from debut of symptoms to the first visit to their family doctor (patient's delay), detailed symptoms and their views and attitudes towards the significance of these symptoms. More than half of the patients first saw their own doctor more than three months after the first symptom: 17/33 (52%) with a change in bowel habits, 12/28 (43%) with rectal bleeding, 11/19 (58%) with abdominal pain and 4/6 (67%) with a palpable mass. Only 7/44 (15%) thought that cancer was the cause of their symptoms, and a similar minority was afraid of an operation or an ostomy. We conclude that the main cause of patient's delay is a lack of knowledge among the patients about the significance of bowel symptoms, rather than fear of cancer, operation or an ostomy. On this basis we recommend that an information campaign about cancer-related bowel symptoms (bleeding, change of bowel habits) should be carried out with the aim of reducing patient's delay and thereby possibly also improving the prognosis through an early diagnosis.

Colonic Neoplasms

Evaluating treatments when a gender by treatment interaction may exist.

We propose a two-stage procedure for investigating whether males and females respond differently to treatment. The size of the first stage is based on the assumption of homogeneity of treatment effects across genders. Using stage I, we test for a gender by treatment interaction. If non-significant, we compute an overall average treatment effect and terminate the study. If we find an apparent interaction at the end of the first stage, we consider each gender separately. Because we now need to estimate treatment effects separately for each gender, we may have a need to collect additional information in a second stage. We consider the performance of our procedure for a normally distributed endpoint as well as for a survival model.

Colonic Neoplasms